http://www.biotechdaily.com.au/index.php

Biotech Daily Home

Biotech Daily covers the major announcements from more than 140 ASX-listed biotech companies as well as the major research institutes and developments in government policy.

Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotech sector.

The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter.

Base-rate subscriptions are $A1450 a year (including GST in Australia) and a 10% discount is available for members of AusBiotech, the Bio-Melbourne Network and Life Sciences Queensland.

Subscribers include biotech directors and CEOs, major pharmaceutical companies, universities, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management.

 

Download subscription form here
 

 

 

Latest News !
 

Biotech Daily Editorial: BNYM & Substantial Shareholder Notices

Dr Boreham's Crucible: Heramed

Ausbiotech: 'Threat To R&D Incentive Worries Sector'

Minister Karen Andrews Talks Biotech

Dr Boreham's Crucible: Oncosil Medical

Federal Election 2019: Policies & Comment

Orthocell Up 377% On 4-Patient Celgro Nerve Regeneration

Actinogen: 'Xanamem Fails Alzheimer's Endpoints'; Falls 71%

Paradigm Raising $78m On PPS Osteoarthritis Pain Trial Results

Federal Budget 2019 - Comment & Analysis

Oncosil Falls 87% On Pancreatic Cancer Radiation Doubts

2018 - The Year In Review

  


 

May BDI-40 Up 6.5%, Big Caps Up 4%, ASX200 Up 1%, NBI Down 6%

 Orthocell Up 418%, LBT 106%, Prescient 42%
Actinogen Down 78
%, Impedimed 40%

 

June 3, 2019

 
May continued the Biotech Daily Top 40 Index (BDI-40) run, breaking through the record collective $10 billion market capitalization mark last month and $11 billion this month.
 
The BDI-40 (which does not include the Big Caps of Cochlear, CSL and Resmed) climbed a further 6.5 percent in May, following the April 18.1 percent jump, easily out-performing the ASX200 which was up 1.1 percent.
 
The three Big Caps of Cochlear, CSL and Resmed rose a collective 4.3 percent and the Nasdaq Biotechnology Index (NBI) fell a further 6.1 percent.
 
For the year to May 31, 2019 the BDI-40 was up 31.3 percent, the Big Caps were up 10.75 percent, the ASX200 improved 6.4 percent and the NBI fell 7.9 percent.
 
In May, 16 of the BDI-40 stocks were up; 11 by more than 10 percent and six by more than 20 percent; while 18 fell, with eight losing more than 10 percent; and six were unchanged.
 
Clinuvel added the most to the market cap index, up $479 million to $1649 million, while the percentage best, from a much lower base, was Orthocell on the news of four Celgro patients regaining muscle function and sensation, up a sensational and muscly $46 million or 418.2 percent to $57 million in the month.
 
LBT was second best on an FDA approval for its APAS Independence, up 106.25 percent  to $33 million, followed by Prescient (41.7%), Clinuvel (40.9% for the month and 184.3% for the year), Telix (21.1%), Patrys (20.8%), Compumedics (18.4%), Oncosil (17.6%), Polynovo (15.9%), Pro Medicus (14.8%) and Avita (11.8%).
 
Actinogen led the falls on non-significance for Xanamem for Alzheimer’s disease, down $45 million or 77.6 percent to $13 million, followed by Impedimed (40.4%), Osprey (25.4%), Alterity (Prana, 17.1%), Benitec (16.2%), Kazia (13.3%), Nanosonics (12.75%) and Universal Biosensors (12.5%).
 
Resmed was up 11.3 percent to $23,394 million, Cochlear rose 5.0 percent to $11,353 million, with CSL up 2.5 percent to $92,240 million.
 
Outside the Top 40, Alcidion, Elixinol, Medadvisor, Painchek and Resonance were all contenders for promotion.
 
The 16 stocks in Cannabis Corner were up 8.1 percent to a collective market capitalization of $1,744 million, with 11 companies up, four down and two unchanged.
 
On the Nasdaq, Vaxart (Biota) recovered from its all-time low, up 66.7 percent to $15 million, Eyepoint (Psivida) was up 3.9 percent to $240 million, Queensland’s Protagonist lost 0.6 percent to $339 million and Israel’s Redhill (with Australian assets) shed 25.5 percent to $234 million.
 
BDI-40 v S&P ASX200 Jun 30, 2006 to May 31, 2019 
 
3-Year Big Caps (Cochlear, CSL, Resmed) to May 31, 2019


BDI-40 ($m) v S&P ASX200 – Year to May 31, 2019 (current, raw data)

 

 

 Click here for Biotech Daily's archive

 

   

Biotech Daily Top 40 With Market Capitalization At May 31, 2019

 

* Biotech Daily editor, David Langsam, owns shares in Acrux, Alterity, Amplia, Benitec, Cynata, Mesoblast
   Nanosonics, Neuren, Patrys, Polynovo, Telix and Volpara, as well as non-biotechnology stocks.
   Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies. 

   These holdings are liable to change: http://www.australianethical.com.au/who-we-invest-in